YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

The Results of Palliative Intensive Hypofractionated Radiotherapy From Patients Having Brain Metastases With Unknown Primary Tumour

dc.contributor.author Izmirli, Mustafa
dc.contributor.author Altin, Sulayman
dc.contributor.author Buyukpolat, M. Yakup
dc.contributor.author Adatepe, M. Ferhan
dc.contributor.author Unsal, Mustafa
dc.date.accessioned 2025-05-10T17:49:59Z
dc.date.available 2025-05-10T17:49:59Z
dc.date.issued 2006
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Izmirli, Mustafa] Yuzuncu Yil Univ, Tip Fak, Radyasyon Onkol Anabilim Dali, TR-65200 Van, Turkey; [Altin, Sulayman; Buyukpolat, M. Yakup; Adatepe, M. Ferhan; Unsal, Mustafa] SSK Okmeydan Egitim & Arastirma Hastanesi, Radyasyon Onkol Klin, Istanbul, Turkey en_US
dc.description.abstract OBJECTIVES We retrospectively examined the results of hypofractionated radiotherapy from 24 patients having brain metastases with unknown primary. METHODS Radiotherapy was administered to 24 patients (20 males (83.4%), 4 females (16.6%), age range 24-75 years) as 10 Gy fraction doses with 10 days intervals for a total of 30 Gy tumour dose in 3 fractions. Antiedema treatment was given to all patients. Karnofsky performance status was 70 for one patient and below 70 for the rest of the patients. Multiple metastases were present in 79.2% of the patients, in 20.8% of the patients there was single lesion and histophatologic diagnosis was present only for this group. 50% of the patients had hemiplegia, 45.8% had hemiparesia, 4.2 % had quadriplegia and 6 patients (25%) had other additional pathologies. Treatment was started at the day of admission for 13 patients. RESULTS The total and partial reliefs in neurological symptoms were seen in 8.3% and 37.5% of patients, respectively. Median survival from diagnosis of brain lesions was 2.87 months. The six months, 1 and 2 years survival rates were 33.3%, 8.33%, and 8.33%, respectively. The prognosis of patients with brain metastases is poor and have similar survival rates from the other poor performance patients (KPS<70). CONCLUSION As a conclusion, short course hypofractionated radiotherapy might be adviced to the patients with poor prognosis. en_US
dc.description.woscitationindex Emerging Sources Citation Index
dc.identifier.endpage 86 en_US
dc.identifier.issn 1300-7467
dc.identifier.issue 2 en_US
dc.identifier.scopusquality Q4
dc.identifier.startpage 81 en_US
dc.identifier.uri https://hdl.handle.net/20.500.14720/17544
dc.identifier.volume 21 en_US
dc.identifier.wos WOS:000439248500005
dc.identifier.wosquality N/A
dc.language.iso tr en_US
dc.publisher Kare Publ en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Brain Neoplasms/Radiotherapy en_US
dc.subject Dose Fractionation en_US
dc.subject Brain Metastases/Prognosis/Survival Analysis/Survival Rate en_US
dc.title The Results of Palliative Intensive Hypofractionated Radiotherapy From Patients Having Brain Metastases With Unknown Primary Tumour en_US
dc.type Article en_US

Files